From space to marketplace

Houston medical devices company using NASA balancing technology prepares for commercial launch

Balancing is important throughout your life, and Zibrio has the tools and tips for you to use to stay centered. Pexels

In her postdoctoral work at NASA, Katharine Forth and her colleague were tasked with finding a new way to track the balance of astronauts on the moon.

"The machines typically used for balance measurement can be as large as a telephone booth, so we invented a new way to measure postural control using a much smaller mechanism that fit inside a moon boot," Forth says.

She didn't know it at the time, but working on this technology would lead her to create Zibrio, The Balance Company with her colleague, Erez Lieberman Aiden.

Zibrio is a health company that aims to be the gold standard of measuring balance. The Zibrio scale calculates users' weight like a typical scale and rates their balance on scale of 1 to 10.

The scale gathers data from your weight, your postural control, your muscles and other factors to calculate the rating. Andrea Case-Rogers, chief experience officer at Zibrio, describes a perfect rating of 10 as elusive for most, or "Simone Biles on a good day."

After seeing their rating, users can identify any problems and start taking steps to improve their balance. Zibrio will also come with a smartphone app, so users can track their balance, any fluctuations and progress over a long-term period.

By using the scale and app together, users can gain a greater understand of what in their lifestyle is helping versus hurting their balance.

From space to the marketplace
After co-founding Zibrio together in 2015, Forth and Aiden have taken the company a long way since then.

Zibrio is a finalist for the 2019 SXSW Pitch in the health and wearables category. In 2015, the company was part of the Texas Medical Center's TMCx medical devices cohort. Both programs highlight the innovative technology being used as well as the big impact that Zibrio could have for both consumers and clinicians.

Zibrio already has conducted clinical trials all over Houston by working with Memorial Hermann and UT Physicians, and the company is currently focused on fundraising. Forth and her team of five will use these funds to get the scale and smartphone app consumer-ready and launched.

The commercial launch for both the scale and app is planned for later this year.

"We're currently finalizing the design with the manufacturer, so they can make the scale available commercially," Forth says. "Since 2015, we've been fundraising, building prototype scales and conducting clinical trials."

Finding balance at any age
A common misconception is that our balance deteriorates in older age. In actuality, a lifetime of behavior and activity affects our balance in later years. Falls are the leading cause of accidental death and unexpected injuries in older adults.

"If you have been mostly sedentary your whole life, by the time you hit your later years, your lower limb strength is weakened affecting your ability to move." Forth says, "so many factors feed into your balance, which means there are so many things that can be done to lower your fall risk."

When Forth and her team ran a balance program at a senior living facility, they halved the number of falls in two years. By creating an awareness of balance, they were able to drive changed behaviors in the seniors, in turn, improving their balance.

According to Case-Rogers, Zibrio is bringing the balance conversation to people in 60s and 70s who want to keep their lifestyle and not deal with mobility and health issues later. They want to show investors that there is a market for wellness product like Zibrio among older people.

Zibrio will sponsor the National Senior Games, the largest multi-sport competition for seniors in the world, this summer in Albuquerque. With over 10,000 athletes, Forth and her team are excited to introduce Zibrio to a larger audience.

Forth firmly believes balance measurements should be a part of routine wellness exams and home self-monitoring, especially in later years.

"When athletes stand on a scale and see their number, it's like a light goes on in their heads and they realize how important balance is," says Forth. "That's what I love, we have this great product that opens up the conversation about and is really helping people in middle age and beyond."

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News